The effect of vitamin B12 on total plasma homocysteine concentration in folate-replete hemodialysis patients.
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Your vote was cast
Thank you for your feedback
Thank you for your feedback
MetadataShow full item record
CitationClin Nephrol. 2003, 59(3):186-9
AbstractAIM: Results from several studies indicate that the total homocysteine (tHcy) concentration in plasma is an independent risk factor for cardiovascular disease in hemodialysis patients. Folic acid is the established mainstay of homocysteine-lowering treatment, but since such treatment does not normalize plasma tHcy concentration in hemodialysis patients, it is of importance to search for additional therapy. METHODS: Twenty-eight folate-replete hemodialysis patients were randomized to 2 equally sized groups, a treatment group and a control group. The treatment group received vitamin B12 tablets at a dose of 2 mg 3 times a week for 6 weeks (after each dialysis session) while the control group received no such treatment. Blood samples were collected before and at the end of the treatment period for analysis of tHcy in plasma and vitamin B12, methylmalonic acid as well as folate in serum. RESULTS: At the end of the study period, serum vitamin B12 concentrations were significantly higher in the treatment group than in the control group. Plasma tHcy concentrations decreased significantly in both groups during the study period. However, there was no difference between the responses of the 2 groups. CONCLUSION: The results of this open, randomized controlled study did not support the hypothesis that treatment with oral vitamin B12 has considerable homocysteine-lowering effect in folate-replete hemodialysis patients.
- Efficacy of folate and vitamin B12 in lowering homocysteine concentrations in hemodialysis patients.
- Authors: Azadibakhsh N, Hosseini RS, Atabak S, Nateghiyan N, Golestan B, Rad AH
- Issue date: 2009 Sep
- Controlled trials of very high dose folic acid, vitamins B12 and B6, intravenous folinic acid and serine for treatment of hyperhomocysteinemia in ESRD.
- Authors: Gonin JM, Nguyen H, Gonin R, Sarna A, Michels A, Masri-Imad F, Bommareddy G, Chassaing C, Wainer I, Loya A, Cary D, Barker LF, Assefi A, Greenspan R, Mahoney D, Wilcox CS
- Issue date: 2003 Jul-Aug
- Hydroxocobalamin reduces hyperhomocysteinemia in end-stage renal disease.
- Authors: Elian KM, Hoffer LJ
- Issue date: 2002 Jul
- Creatine supplementation does not decrease total plasma homocysteine in chronic hemodialysis patients.
- Authors: Taes YE, Delanghe JR, De Bacquer D, Langlois M, Stevens L, Geerolf I, Lameire NH, De Vriese AS
- Issue date: 2004 Dec
- Hyperhomocysteinaemia, folate and vitamin B12 in unsupplemented haemodialysis patients: effect of oral therapy with folic acid and vitamin B12.
- Authors: Billion S, Tribout B, Cadet E, Queinnec C, Rochette J, Wheatley P, Bataille P
- Issue date: 2002 Mar